Literature DB >> 17653763

Posterior reversible encephalopathy in a child with Langerhans cell histiocytosis following allogeneic PBSCT treatment with cyclosporine.

Chi-Chieh Lai1, Shyi-Jou Chen, Shao-Hung Lien, Chung-Ping Lo, Shin-Nang Cheng.   

Abstract

Posterior reversible encephalopathy syndrome (PRES) is associated with a specific disorder of cerebrovascular autoregulation of multiple etiologies. This syndrome had been subsequently described in numerous medical conditions, including hypertensive encephalopathy, pre-eclampsia and the use with immunosuppressive drugs. Here, we report a child suffering from Langerhans cell histocytosis developing into PRES following immunosuppressive therapy. Symptoms and neuroimaging abnormalities were complete resolution subsequent to the withdrawal of cyclosporine. Although PRES is rarely seen among children, it should always be considered in the differential diagnosis of acute neurological illness, especially undergoing immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17653763     DOI: 10.1007/s00431-007-0564-2

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  10 in total

1.  Assessment of vasogenic edema in eclampsia using diffusion imaging.

Authors:  S T Engelter; J M Provenzale; J R Petrella
Journal:  Neuroradiology       Date:  2000-11       Impact factor: 2.804

2.  Quantitative assessment of diffusion abnormalities in posterior reversible encephalopathy syndrome.

Authors:  J M Provenzale; J R Petrella; L C Cruz; J C Wong; S Engelter; D P Barboriak
Journal:  AJNR Am J Neuroradiol       Date:  2001-09       Impact factor: 3.825

3.  Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions.

Authors:  S O Casey; R C Sampaio; E Michel; C L Truwit
Journal:  AJNR Am J Neuroradiol       Date:  2000-08       Impact factor: 3.825

4.  Disturbance of blood-brain barrier after bone-marrow transplantation.

Authors:  J P Sloane; K Y Lwin; M E Gore; R L Powles; J F Smith
Journal:  Lancet       Date:  1985-08-03       Impact factor: 79.321

5.  Reversible posterior leucoencephalopathy syndrome associated with bone marrow transplantation.

Authors:  H A Teive; I V Brandi; C H Camargo; M A Bittencourt; C M Bonfim; M L Friedrich; C R de Medeiros; L C Werneck; R Pasquini
Journal:  Arq Neuropsiquiatr       Date:  2001-09       Impact factor: 1.420

Review 6.  Cerebral autoregulation.

Authors:  S Strandgaard; O B Paulson
Journal:  Stroke       Date:  1984 May-Jun       Impact factor: 7.914

7.  Hypertension induced reversible posterior leukoencephalopathy syndrome: a report of two cases.

Authors:  Z Birsin Ozcakar; Mesiha Ekim; Suat Fitoz; Serap Teber; Selda Hizel; Banu Acar; Selcuk Yüksel; Fatos Yalcinkaya
Journal:  Eur J Pediatr       Date:  2004-12       Impact factor: 3.183

Review 8.  Neuroimaging in posterior reversible encephalopathy syndrome.

Authors:  C Lamy; C Oppenheim; J F Méder; J L Mas
Journal:  J Neuroimaging       Date:  2004-04       Impact factor: 2.486

9.  A reversible posterior leukoencephalopathy syndrome.

Authors:  J Hinchey; C Chaves; B Appignani; J Breen; L Pao; A Wang; M S Pessin; C Lamy; J L Mas; L R Caplan
Journal:  N Engl J Med       Date:  1996-02-22       Impact factor: 91.245

10.  Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images.

Authors:  Diego J Covarrubias; Patrick H Luetmer; Norbert G Campeau
Journal:  AJNR Am J Neuroradiol       Date:  2002 Jun-Jul       Impact factor: 3.825

  10 in total
  2 in total

Review 1.  Posterior reversible encephalopathy syndrome in children with kidney diseases.

Authors:  Kenji Ishikura; Yuko Hamasaki; Tomoyuki Sakai; Hiroshi Hataya; Robert H Mak; Masataka Honda
Journal:  Pediatr Nephrol       Date:  2011-05-11       Impact factor: 3.714

2.  Lysergic acid amide-induced posterior reversible encephalopathy syndrome with status epilepticus.

Authors:  Stephane Legriel; Fabrice Bruneel; Odile Spreux-Varoquaux; Aurelie Birenbaum; Marie Laure Chadenat; François Mignon; Nathalie Abbosh; Matthieu Henry-Lagarrigue; Laure Revault D'Allonnes; Pierre Guezennec; Gilles Troche; Jean Pierre Bedos
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.